(Q45185321)

English

Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial

scientific article published in December 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Norman R Zinner

1

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Mohamed Bidair

2

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Arthur Centeno

3

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Kevin Tomera

4

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

language of work or name

0 references

publication date

1 December 2004

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

64

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

1177-1181

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Comparison of LHRH Analogue (Zoladex) with Orchiectomy in Patients with Metastatic Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.033

7 January 2021

Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.033

7 January 2021

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.033

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.033

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.033

7 January 2021

Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.033

7 January 2021

Flutamide Eliminates the Risk of Disease Flare in Prostatic Cancer Patients Treated with a Luteinizing Hormone-Releasing Hormone Agonist

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.033

7 January 2021

A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperat

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.033

7 January 2021

Clinical efficacy and safety of a new leuprorelin acetate depot formulation in patients with advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.033

7 January 2021

Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.033

7 January 2021

Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.033

7 January 2021

Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.07.033

7 January 2021

Identifiers

10.1016/J.UROLOGY.2004.07.033

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45185321&oldid=2069382090"